Literature DB >> 2788005

Childhood leukaemia in The Netherlands, 1973-1986: temporary variation of the incidence of acute lymphocytic leukaemia in young children.

J W Coebergh1, A van der Does-van den Berg, E R van Wering, H A van Steensel-Moll, H A Valkenburg, M B van't Veer, P I Schmitz, G E van Zanen.   

Abstract

The incidence of childhood leukaemia in The Netherlands in the period 1973-1986 was studied by means of the DCLSG nationwide register, which lists all patients according to bone marrow slides classified in the DCLSG central laboratory. Acute lymphocytic leukaemia (ALL) accounted for 81% of cases, acute non-lymphocytic leukaemia (ANLL) for 13%, chronic myelocytic leukaemia (CML) for 2.5%, and acute unclassifiable leukaemia (AUL) for 3%. The peak incidence of ALL was at age 3, common-ALL and pre B-ALL comprising about 95% of the immunophenotypes at this age. Incidence rates for ALL remained stable between 1973 and 1978 at 2.85 cases per 10(5) children per year, exhibited a temporary increase between 1979 and 1984 to 3.60 and dropped back to the lower, previous level in 1985 and 1986. This rise was seen mainly among children in the 1-4 year age group, especially at age 3, and those with common-ALL and an initial WBC less than 5.0 x 10(9) l-1. Cumulative incidence rates per year of birth were fairly homogeneous up to age 6, except for the 1978 birth cohort which exhibited higher rates. Incidence rates for ANLL, CML and AUL remained stable over time. Changes in ascertainment, declining birth rates and a 50% decrease in childhood mortality, e.g. from infectious diseases, could not explain this temporary variation. Moreover, incidence rates in this survey appeared to be similar to those reported in various developed countries for the same period. As far as the aetiology of childhood common-ALL is concerned, therefore, the Dutch data appear to support the hypothesis of 'random mutation' as well as that of a limited role of environmental factors.

Entities:  

Mesh:

Year:  1989        PMID: 2788005      PMCID: PMC2246965          DOI: 10.1038/bjc.1989.20

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Descriptive epidemiology of childhood leukaemia and lymphoma in Great Britain.

Authors:  C A Stiller
Journal:  Leuk Res       Date:  1985       Impact factor: 3.156

2.  Hypothesis: the environment is a major determinant of the immunological sub-type of lymphoma and acute lymphoblastic leukaemia in children.

Authors:  B Ramot; I Magrath
Journal:  Br J Haematol       Date:  1982-02       Impact factor: 6.998

3.  Immunological typing of acute lymphoblastic leukaemia.

Authors:  H J van der Reijden; E R van Wering; J M van de Rijn; C J Melief; M B van 't Veer; H Behrendt; A E von dem Borne
Journal:  Scand J Haematol       Date:  1983-04

4.  Time space distribution of childhood leukaemia in the Netherlands.

Authors:  H A van Steensel-Moll; H A Valkenburg; J P Vandenbroucke; G E van Zanen
Journal:  J Epidemiol Community Health       Date:  1983-06       Impact factor: 3.710

5.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

6.  The epidemiology of childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma in Israel between 1976 and 1981.

Authors:  B Ramot; I Ben-Bassat; A Brecher; R Zaizov; M Modan
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

7.  Childhood cancer incidence: geographical and temporal variations.

Authors:  N E Breslow; B Langholz
Journal:  Int J Cancer       Date:  1983-12-15       Impact factor: 7.396

8.  The inter-regional epidemiological study of childhood cancer (IRESCC): a case control study of aetiological factors in leukaemia and lymphoma.

Authors:  P A McKinney; R A Cartwright; J M Saiu; J R Mann; C A Stiller; G J Draper; A L Hartley; P A Hopton; J M Birch; J A Waterhouse
Journal:  Arch Dis Child       Date:  1987-03       Impact factor: 3.791

9.  Incidence of childhood leukaemia in The Netherlands (1973-1980).

Authors:  H A van Steensel-Moll; H A Valkenburg; G E van Zanen
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

10.  Childhood leukaemia in North West England 1954-1977: epidemiology, incidence and survival.

Authors:  J M Birch; R Swindell; H B Marsden; P H Morris Jones
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

View more
  5 in total

1.  Re: "Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands".

Authors:  Daniel Wollschläger; Maria Blettner; Roman Pokora
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

2.  Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007.

Authors:  R Marcos-Gragera; J Galceran; C Martos; A L de Munain; M Vicente-Raneda; C Navarro; J R Quirós-Garcia; M-J Sánchez; E Ardanaz; M Ramos; A Mateos; D Salmerón; S Felipe; R Peris-Bonet
Journal:  Clin Transl Oncol       Date:  2016-07-22       Impact factor: 3.405

3.  Childhood leukaemias in New Zealand: time trends and ethnic differences.

Authors:  J D Dockerty; B Cox; M G Cockburn
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

4.  Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands.

Authors:  Johanna M Meulepas; Cécile M Ronckers; Anne M J B Smets; Rutger A J Nievelstein; Patrycja Gradowska; Choonsik Lee; Andreas Jahnen; Marcel van Straten; Marie-Claire Y de Wit; Bernard Zonnenberg; Willemijn M Klein; Johannes H Merks; Otto Visser; Flora E van Leeuwen; Michael Hauptmann
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

5.  Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia.

Authors:  David T Teachey; Stephen P Hunger; Mignon L Loh
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.